A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1)
This study is testing a new experimental medication called AZD9574, both by itself and mixed with other cancer treatments. Researchers want to see how safe the drug is and if it can help patients with advanced solid tumors that have come back or continued to grow.
You might be able to join if you have specific advanced cancers like breast, ovarian, prostate, or pancreatic cancer that have certain genetic changes. Participants also need to be able to do daily activities normally and have organs working well enough to handle the treatments.
During the study, you will receive the experimental medication AZD9574 along with regular check-ups to monitor your safety and how your body responds. You may also receive other approved anti-cancer medications depending on the specific part of the study you join.
The study is currently open and looking for participants at multiple medical centers in California, United States. Your care team will guide you through all the details and schedule visits at the nearest location.
- 1Tests a new experimental drug called AZD9574 for advanced solid tumors
- 2Looking for patients with specific genetic mutations in certain cancer types
- 3Currently recruiting participants at locations in California
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.